Pharmacology

The cytokine inhibitor ISIS 104838 extends bioavailability upon oral intake

Published in Gene Therapy Weekly, August 12th, 2004

The cytokine inhibitor ISIS 104838 extends bioavailability upon oral intake.

According to a study from Belgium, "an in vivo study was performed to determine the tolerability and pharmacokinetics of ISIS 104838, a phosphorothioate antisense oligonucleotide targeting human tumor necrosis factor alpha (TNF-alpha) mRNA, following multidose administration via intravenous and oral routes. Oral tablet formulations of ISIS 104838 were preformulated with the permeation enhancer sodium caprate in an enteric-coated solid dosage form."

"The average plasma bioavailability of ISIS 104838 was 1.4% relative to IV. The tissue distribution profile was similar...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-08-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry